5/9/2025

Edwards Lifesciences 2025 Annual Meeting of Stockholders May 8, 2025 Presenters Nick Valeriani, Chairman of the Board Bernard Zovighian, CEO ...

Source: Finnhub

5/9/2025

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where Edwards Lifesciences Corporation (NYSE:EW) stands against other best medical device stocks to buy now. Trump’s Tariffs Are Dividing the Medical Community On April 16, CNBC reported that Trump’s tariffs […]

Source: Yahoo

5/8/2025

Edwards Lifesciences ( NYSE:EW ) First Quarter 2025 Results Key Financial Results Revenue: US$1.41b (up 6.2% from 1Q...

Source: Yahoo

5/7/2025

Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications Inc. (VZ), Bristol-Myers Squibb Co. (BMY) and Canadian Pacific Kansas City Ltd. (CP), as well a micro-cap stock Nova LifeStyle, Inc. (NVFY).

Source: Yahoo

5/6/2025

IRVINE, Calif., May 06, 2025--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025.

Source: Yahoo

5/2/2025

Edwards Lifesciences (NYSE:EW) recently celebrated the FDA approval of its SAPIEN 3 TAVR therapy for asymptomatic aortic stenosis patients, a significant development in cardiac care. This milestone, coupled with robust Q1 earnings and updated financial guidance, likely bolstered investors' confidence, contributing to a 5% share price increase over the past month. The company’s advancements align with broader market trends, marked by a 2% rise, driven by strong earnings and positive economic...

Source: Yahoo

5/1/2025

Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients.

Source: Yahoo

5/1/2025

IRVINE, Calif., May 01, 2025--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.

Source: Yahoo

5/1/2025

We recently published a list of How Did Jim Cramer’s 12 Bold Predictions Play Out?. In this article, we are going to take a look at where Edwards Lifesciences Corporation (NYSE:EW) stands against other stocks that Jim Cramer recently discussed. During the most recent episode of Mad Money, Jim Cramer revisited the recent turbulence in […]

Source: Yahoo

4/30/2025

Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors

Source: MarketWatch

4/28/2025

Dow Jones aerospace giant Boeing is approaching a new buy point, while Spotify earnings loom ahead of the market open Tuesday.

Source: Yahoo

4/25/2025

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day

Source: MarketWatch

4/24/2025

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

Source: Yahoo

4/24/2025

Edwards Lifesciences (NYSE:EW) recently announced its updated guidance, projecting second-quarter 2025 sales between $1.45 billion and $1.53 billion, alongside first-quarter results showing a rise in sales and net income compared to the previous year. This aligns with a broader market trend where the S&P 500 and Nasdaq Composite surged, driven by positive earnings reports and easing concerns over tariffs. The company's 2.2% price move over the last quarter reflects the general optimism but...

Source: Yahoo

4/24/2025

Texas Instruments, Mondelez downgraded: Wall Street's top analyst calls

Source: Yahoo

4/24/2025

Q1 2025 Edwards Lifesciences Corp Earnings Call

Source: Yahoo

4/24/2025

Source: Fintel

4/24/2025

The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity constraints that have dogged its core business.

Source: Yahoo

4/24/2025

Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.

Source: Yahoo

4/24/2025

Edwards Lifesciences Corp (EW) reports an 8% increase in total sales, raises full-year guidance, and achieves significant product approvals in Q1 2025.

Source: Yahoo